Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 2/2015

01-03-2015 | Review

Pathological and protective immunity to Pneumocystis infection

Authors: Taylor Eddens, Jay K. Kolls

Published in: Seminars in Immunopathology | Issue 2/2015

Login to get access

Abstract

Pneumocystis jirovecii is a common opportunistic infection in the HIV-positive population and is re-emerging as a growing clinical concern in the HIV-negative immunosuppressed population. Newer targeted immunosuppressive therapies and the discovery of rare genetic mutations have furthered our understanding of the immunity required to clear Pneumocystis infection. The immune system can also mount a pathologic response against Pneumocystis following removal of immunosuppression and result in severe damage to the host lung. The current review will examine the most recent epidemiologic studies about the incidence of Pneumocystis in the HIV-positive and HIV-negative populations in the developing and developed world and will detail methods of diagnosis for Pneumocystis pneumonia. Finally, this review aims to summarize the known mediators of immunity to Pneumocystis and detail the pathologic immune response leading to Pneumocystis-related immune reconstitution inflammatory syndrome.
Literature
1.
Chabe M et al (2011) Pneumocystis: from a doubtful unique entity to a group of highly diversified fungal species. FEMS Yeast Res 11:2–17CrossRefPubMed
2.
Centers for Disease C (1981) Pneumocystis pneumonia—Los Angeles. MMWR Morb Mortal Wkly Rep 30:250–252
3.
4.
Walzer PD et al (2008) Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985–2006. Clin Infect Dis : Off Publ Infect Diseases Soc Am 46:625–633CrossRef
5.
Antiretroviral Therapy, Cohort C et al (2009) Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis 48:1138–1151CrossRef
6.
7.
8.
Ruffini DD, Madhi SA (2002) The high burden of Pneumocystis carinii pneumonia in African HIV-1-infected children hospitalized for severe pneumonia. AIDS 16:105–112CrossRefPubMed
9.
Chakaya JM et al (2003) Pneumocystis carinii pneumonia in HIV/AIDS patients at an urban district hospital in Kenya. East Afr Med J 80:30–35PubMed
10.
Tansuphasawadikul S et al (2005) Clinical features, etiology and short term outcomes of interstitial pneumonitis in HIV/AIDS patients. Southeast Asian J Trop Med Public Health 36:1469–1478PubMed
11.
Nissapatorn V et al (2004) Spectrum of opportunistic infections among HIV-infected patients in Malaysia. Southeast Asian J Trop Med Public Health 35(Suppl 2):26–32PubMed
12.
Udwadia ZF et al (2005) Pneumocystis carinii pneumonia in HIV infected patients from Mumbai. J Assoc Physicians India 53:437–440PubMed
13.
Panizo MM et al (2008) Pneumocystosis in Venezuelan patients: epidemiology and diagnosis (2001–2006). Rev Iberoam Micol 25:226–231CrossRefPubMed
14.
Chernilo S et al (2005) Lung diseases among HIV infected patients admitted to the “Instituto Nacional del Torax” in Santiago, Chile. Rev Med Chil 133:517–524CrossRefPubMed
15.
Mikaelsson L et al (2006) Pneumocystis pneumonia—a retrospective study 1991–2001 in Gothenburg, Sweden. J Infect 53:260–265CrossRefPubMed
16.
17.
Carmona EM, Limper AH (2011) Update on the diagnosis and treatment of Pneumocystis pneumonia. Ther Adv Respir Dis 5:41–59CrossRefPubMed
18.
Catherinot E et al (2010) Pneumocystis jirovecii Pneumonia. Infect Dis Clin N Am 24:107–138CrossRef
19.
Goto N, Oka S (2011) Pneumocystis jirovecii pneumonia in kidney transplantation. Transpl Infect Dis 13:551–558CrossRefPubMed
20.
Mussini C et al (2008) Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. AIDS 22:2461–2469CrossRefPubMed
21.
Neff RT et al (2009) Analysis of USRDS: incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation 88:135–141CrossRefPubMed
22.
Sepkowitz KA (2002) Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clin Infect Dis 34:1098–1107CrossRefPubMed
23.
Wolfe RA et al (2010) Trends in organ donation and transplantation in the United States, 1999–2008. Am J Transplant 10:961–972CrossRefPubMed
24.
Rodriguez M, Fishman JA (2004) Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 17:770–782, table of contentsCrossRefPubMedCentralPubMed
25.
Louie GH et al (2010) Trends in hospitalizations for Pneumocystis jiroveci pneumonia among patients with rheumatoid arthritis in the US: 1996–2007. Arthritis Rheum 62:3826–3827CrossRefPubMedCentralPubMed
26.
Stamp LK, Hurst M (2010) Is there a role for consensus guidelines for P. jiroveci pneumonia prophylaxis in immunosuppressed patients with rheumatic diseases? J Rheumatol 37:686–688CrossRefPubMed
27.
Falagas ME et al (2007) Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol 26:663–670CrossRefPubMed
28.
Poppers DM, Scherl EJ (2008) Prophylaxis against Pneumocystis pneumonia in patients with inflammatory bowel disease: toward a standard of care. Inflamm Bowel Dis 14:106–113CrossRefPubMed
29.
De Castro N et al (2005) Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplant 36:879–883CrossRefPubMed
30.
Martin-Garrido I et al (2013) Pneumocystis pneumonia in patients treated with rituximab. Chest 144:258–265CrossRefPubMed
31.
Monnet X et al (2008) Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection. Crit Care 12:R28CrossRefPubMedCentralPubMed
32.
Mori S, Sugimoto M (2012) Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis. Rheumatology (Oxford) 51:2120–2130CrossRef
33.
34.
Kanne JP et al (2012) Pneumocystis jiroveci pneumonia: high-resolution CT findings in patients with and without HIV infection. AJR Am J Roentgenol 198:W555–W561CrossRefPubMed
35.
Wakefield AE et al (1990) Detection of Pneumocystis carinii with DNA amplification. Lancet 336:451–453CrossRefPubMed
36.
Reid AB et al (2011) Pneumocystis jirovecii pneumonia in non-HIV-infected patients: new risks and diagnostic tools. Curr Opin Infect Dis 24:534–544CrossRefPubMed
37.
Flori P et al (2004) Comparison between real-time PCR, conventional PCR and different staining techniques for diagnosing Pneumocystis jiroveci pneumonia from bronchoalveolar lavage specimens. J Med Microbiol 53:603–607CrossRefPubMed
38.
Desmet S et al (2009) Serum (1–3)-beta-D-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. J Clin Microbiol 47:3871–3874CrossRefPubMedCentralPubMed
39.
Nakamura H et al (2009) Clinical utility of serum beta-D-glucan and KL-6 levels in Pneumocystis jirovecii pneumonia. Intern Med 48:195–202CrossRefPubMed
40.
41.
Cushion MT et al (2010) Echinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection. PLoS ONE 5:e8524CrossRefPubMedCentralPubMed
42.
Itatani CA (1994) Ultrastructural demonstration of a pore in the cyst wall of Pneumocystis carinii. J Parasitol 80:644–648CrossRefPubMed
43.
44.
45.
46.
Schildgen V et al. 2014. Pneumocystis jirovecii can be productively cultured in differentiated CuFi-8 airway cells. MBio 5
47.
Edman JC et al (1988) Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature 334:519–522CrossRefPubMed
48.
Stringer SL et al (1989) Sequence from ribosomal RNA of Pneumocystis carinii compared to those of four fungi suggests an ascomycetous affinity. J Protozool 36:14S–16SCrossRefPubMed
49.
Aliouat-Denis CM et al (2008) Pneumocystis species, co-evolution and pathogenic power. Infect Genet Evol 8:708–726CrossRefPubMed
50.
Frenkel JK (1976) Pneumocystis jiroveci n. sp. from man: morphology, physiology, and immunology in relation to pathology. Natl Cancer Inst Monogr 43:13–30PubMed
51.
Keely SP et al (2003) Evolution and speciation of Pneumocystis. J Eukaryot Microbiol 50(Suppl):624–626CrossRefPubMed
52.
Cisse OH et al (2012) De novo assembly of the Pneumocystis jirovecii genome from a single bronchoalveolar lavage fluid specimen from a patient. MBio 4:e00428–12CrossRefPubMedCentralPubMed
53.
Kluge RM et al (1978) Combination of pentamidine and trimethoprim-sulfamethoxazole in therapy of Pneumocystis carinii pneumonia in rats. Antimicrob Agents Chemother 13:975–978CrossRefPubMedCentralPubMed
54.
Chandler FW et al (1979) Pneumocystis pneumonia. Animal model: Pneumocystis cartinii pneumonia in the immunosuppressed rat. Am J Pathol 95:571–574PubMedCentralPubMed
55.
Hughes WT et al (1973) Pneumocystis carinii pneumonitis in children with malignancies. J Pediatr 82:404–415CrossRefPubMed
56.
Phair J et al (1990) The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med 322:161–165CrossRefPubMed
57.
Shellito J et al (1990) A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes. J Clin Invest 85:1686–1693CrossRefPubMedCentralPubMed
58.
59.
60.
Mogensen TH (2013) STAT3 and the Hyper-IgE syndrome: clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties. JAKSTAT 2:e23435PubMedCentralPubMed
61.
62.
63.
Lund FE et al (2006) B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection. J Immunol 176:6147–6154CrossRefPubMed
64.
Al-Saud BK et al (2013) Clinical, immunological, and molecular characterization of hyper-IgM syndrome due to CD40 deficiency in eleven patients. J Clin Immunol 33:1325–1335CrossRefPubMed
65.
Tsai HY et al. 2012. X-linked hyper-IgM syndrome with CD40LG mutation: two case reports and literature review in Taiwanese patients. J Microbiol Immunol Infect
66.
Costa-Carvalho BT et al (2011) Pulmonary complications in patients with antibody deficiency. Allergol Immunopathol (Madr) 39:128–132CrossRef
67.
68.
69.
70.
Lasbury ME et al (2007) Polyamine-mediated apoptosis of alveolar macrophages during Pneumocystis pneumonia. J Biol Chem 282:11009–11020CrossRefPubMed
71.
Steele C et al (2003) Alveolar macrophage-mediated killing of Pneumocystis carinii f. sp. muris involves molecular recognition by the Dectin-1 beta-glucan receptor. J Exp Med 198:1677–1688CrossRefPubMedCentralPubMed
72.
Wells J et al (2006) Complement and Fc function are required for optimal antibody prophylaxis against Pneumocystis carinii pneumonia. Infect Immun 74:390–393CrossRefPubMedCentralPubMed
73.
McAllister F et al (2004) T cytotoxic-1 CD8+ T cells are effector cells against pneumocystis in mice. J Immunol 172:1132–1138CrossRefPubMed
74.
Mori S, Levin P (2009) A brief review of potential mechanisms of immune reconstitution inflammatory syndrome in HIV following antiretroviral therapy. Int J STD AIDS 20:447–452CrossRefPubMed
75.
Martin-Blondel G et al (2012) Pathogenesis of the immune reconstitution inflammatory syndrome in HIV-infected patients. Curr Opin Infect Dis 25:312–320CrossRefPubMed
76.
Muller M et al (2010) Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 10:251–261CrossRefPubMedCentralPubMed
77.
Achenbach CJ et al (2012) Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection. Clin Infect Dis 54:424–433CrossRefPubMedCentralPubMed
78.
Novak RM et al (2012) Immune reconstitution inflammatory syndrome: incidence and implications for mortality. AIDS 26:721–730CrossRefPubMed
79.
Grant PM et al (2010) Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS ONE 5:e11416CrossRefPubMedCentralPubMed
80.
Jagannathan P et al (2009) Life-threatening immune reconstitution inflammatory syndrome after Pneumocystis pneumonia: a cautionary case series. AIDS 23:1794–1796CrossRefPubMed
81.
Zolopa A et al (2009) Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS ONE 4:e5575CrossRefPubMedCentralPubMed
82.
Wright TW et al (1997) Analysis of cytokine mRNA profiles in the lungs of Pneumocystis carinii-infected mice. Am J Respir Cell Mol Biol 17:491–500CrossRefPubMed
83.
Wright TW et al (1999) Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia. J Clin Invest 104:1307–1317CrossRefPubMedCentralPubMed
84.
Bhagwat SP et al (2010) Anti-CD3 antibody decreases inflammation and improves outcome in a murine model of Pneumocystis pneumonia. J Immunol 184:497–502CrossRefPubMedCentralPubMed
85.
Gigliotti F et al (2006) Sensitized CD8+ T cells fail to control organism burden but accelerate the onset of lung injury during Pneumocystis carinii pneumonia. Infect Immun 74:6310–6316CrossRefPubMedCentralPubMed
86.
Swain SD et al (2006) CD8 T cells modulate CD4 T-cell and eosinophil-mediated pulmonary pathology in pneumocystis pneumonia in B-cell-deficient mice. Am J Pathol 168:466–475CrossRefPubMedCentralPubMed
87.
Hori S et al (2002) CD25+ CD4+ regulatory T cells suppress CD4+ T cell-mediated pulmonary hyperinflammation driven by Pneumocystis carinii in immunodeficient mice. Eur J Immunol 32:1282–1291CrossRefPubMed
88.
Ruan S et al (2002) Local delivery of the viral interleukin-10 gene suppresses tissue inflammation in murine Pneumocystis carinii infection. Infect Immun 70:6107–6113CrossRefPubMedCentralPubMed
89.
McKinley L et al (2006) Regulatory T cells dampen pulmonary inflammation and lung injury in an animal model of pneumocystis pneumonia. J Immunol 177:6215–6226CrossRefPubMedCentralPubMed
90.
91.
Atochina-Vasserman EN et al (2009) Immune reconstitution during Pneumocystis lung infection: disruption of surfactant component expression and function by S-nitrosylation. J Immunol 182:2277–2287CrossRefPubMedCentralPubMed
92.
Linke MJ et al (2013) Characterization of a distinct host response profile to Pneumocystis murina asci during clearance of pneumocystis pneumonia. Infect Immun 81:984–995CrossRefPubMedCentralPubMed
93.
Ricks D et al. 2013. Dectin immunoadhesins and Pneumocystis pneumonia. Infect Immun
94.
Bellamy RJ. 2008. HIV: treating Pneumocystis pneumonia (PCP). Clin Evid (Online) 2008
95.
Helweg-Larsen J et al (2009) Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. J Antimicrob Chemother 64:1282–1290CrossRefPubMedCentralPubMed
96.
Jick H (1982) Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients. Rev Infect Dis 4:426–428CrossRefPubMed
97.
Phillips E, Mallal S (2007) Drug hypersensitivity in HIV. Curr Opin Allergy Clin Immunol 7:324–330CrossRefPubMed
98.
Hirsch HH et al (2004) Immune reconstitution in HIV-infected patients. Clin Infect Dis 38:1159–1166CrossRefPubMed
99.
Barry SM et al (2002) Immune reconstitution pneumonitis following Pneumocystis carinii pneumonia in HIV-infected subjects. HIV Med 3:207–211CrossRefPubMed
100.
Koval CE et al (2002) Immune reconstitution syndrome after successful treatment of Pneumocystis carinii pneumonia in a man with human immunodeficiency virus type 1 infection. Clin Infect Dis 35:491–493CrossRefPubMed
Metadata
Title
Pathological and protective immunity to Pneumocystis infection
Authors
Taylor Eddens
Jay K. Kolls
Publication date
01-03-2015
Publisher
Springer Berlin Heidelberg
Published in
Seminars in Immunopathology / Issue 2/2015
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-014-0459-z

Other articles of this Issue 2/2015

Seminars in Immunopathology 2/2015 Go to the issue

Review

The cross-talk between opportunistic fungi and the mammalian host via microbiota’s metabolism

Review

Candida albicans phospholipomannan: a sweet spot for controlling host response/inflammation

Review

Pattern recognition receptors in antifungal immunity

Review

Interference of Aspergillus fumigatus with the immune response

Review

Host genetics of invasive Aspergillus and Candida infections

Review

Novel insights into host-fungal pathogen interactions derived from live-cell imaging
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits